Does Blue Cross Blue Shield of Michigan Cover Tirzepatide (Mounjaro)?

How BCBSM Classifies Tirzepatide on Its Formulary

Blue Cross Blue Shield of Michigan places Mounjaro (tirzepatide) on its prescription drug formulary for type 2 diabetes management, typically under a specialty or non-preferred brand tier. The exact tier varies by plan type. BCBSM PPO, HMO (Blue Care Network), and Medicare Advantage plans each maintain separate formulary documents updated annually.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The FDA approved Mounjaro in May 2022 specifically as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. That approval distinguishes it from Zepbound, which the FDA approved in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. BCBSM treats these as two separate coverage determinations. A patient prescribed Mounjaro for diabetes follows the endocrine/metabolic drug prior authorization pathway, while a patient prescribed Zepbound for weight loss faces the anti-obesity medication policy, which carries far stricter exclusions.

BCBSM publishes its formulary search tool online, and patients can verify their specific tier placement by entering "tirzepatide" or "Mounjaro" into the drug lookup. Tier placement directly affects the copay or coinsurance percentage a member pays at the pharmacy counter [1].

Prior Authorization Requirements for Mounjaro

BCBSM requires prior authorization (PA) for all GLP-1 receptor agonist prescriptions, including tirzepatide. This is standard practice. The PA process confirms a clinical diagnosis of type 2 diabetes, verifies that the patient has tried and failed (or has a documented contraindication to) at least one first-line oral agent, and establishes that the prescriber is managing the patient's metabolic health.

According to the American Diabetes Association's 2024 Standards of Care, GLP-1 receptor agonists are recommended as second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, and may be considered first-line in certain clinical scenarios. BCBSM's PA criteria generally align with these guidelines but still require documentation of metformin use or intolerance.

The prescribing physician must submit clinical notes showing a current HbA1c level (typically ≥7.0% despite current therapy), a list of prior diabetes medications with dates and outcomes, and confirmation that the patient is following dietary and exercise recommendations. BCBSM's standard PA review takes up to 72 hours. Urgent requests, defined as situations where delay could seriously jeopardize the patient's health, receive a 24-hour turnaround per Michigan Department of Insurance and Financial Services (DIFS) regulations.

If the PA is denied, the denial letter must include a specific clinical rationale. The patient and prescriber both have the right to appeal [2].

Step Therapy: What You Must Try First

Step therapy is the most common barrier Michigan patients encounter when seeking Mounjaro coverage through BCBSM. Most BCBSM commercial plans require documented use of at least one, and sometimes two, lower-cost diabetes medications before tirzepatide is authorized.

The typical step therapy sequence looks like this: metformin (first-line), then an SGLT2 inhibitor or sulfonylurea (second-line), and only then a GLP-1 receptor agonist like tirzepatide. Some BCBSM plans also require a trial of semaglutide (Ozempic) before approving Mounjaro, since Ozempic may sit on a preferred formulary tier.

A key clinical point: the SURPASS-2 trial (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.46% compared to 1.86% for semaglutide 1 mg at 40 weeks, a statistically significant difference (P<0.001). This head-to-head data can support a physician's argument that tirzepatide offers superior glycemic control when requesting an exception to step therapy requirements [3].

Patients who experience documented side effects from metformin (gastrointestinal intolerance is the most common reason) can often bypass the first step. A letter from the prescriber detailing the adverse reaction, along with pharmacy records showing the metformin prescription was filled and discontinued, typically satisfies BCBSM's exception criteria.

Coverage for Weight Loss (Zepbound) Under BCBSM

This is where coverage becomes difficult. Most BCBSM plans exclude anti-obesity medications from their pharmacy benefit. Zepbound (tirzepatide 2.5 mg to 15 mg for chronic weight management) falls under this exclusion for the majority of BCBSM commercial members.

The SURMOUNT-1 trial (N=2,539) showed that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% for placebo, making it the most effective anti-obesity medication studied in a phase 3 trial to date [4]. Despite these results, BCBSM has been slow to add weight management indications to covered benefits.

Some exceptions exist. Certain BCBSM employer-sponsored plans have added obesity medication coverage as a rider or supplemental benefit, particularly large self-insured employers in Michigan's automotive and manufacturing sectors. Blue Care Network HMO plans occasionally differ from BCBSM PPO plans in their anti-obesity medication policies. The only reliable way to confirm coverage is to call the member services number on the back of the insurance card and ask specifically about "anti-obesity medication" or "chronic weight management drug" coverage.

Medicare Part D plans administered by BCBSM also exclude weight-loss medications, consistent with the longstanding CMS statutory exclusion of drugs used for weight loss. Legislative efforts, including the proposed Treat and Reduce Obesity Act, aim to change this, but as of mid-2026, the exclusion remains in effect for traditional Medicare [5].

What Mounjaro Costs with BCBSM Coverage

Out-of-pocket costs for Mounjaro under BCBSM vary by plan design. Here are the most common scenarios for Michigan members with approved prior authorization for the type 2 diabetes indication.

On a BCBSM PPO plan with a preferred specialty tier placement, members typically pay a copay between $50 and $150 per 28-day supply. Non-preferred brand tier placement pushes that higher, sometimes to 25% to 33% coinsurance after deductible. A Blue Care Network HMO plan may offer a fixed copay of $25 to $75 if Mounjaro lands on the preferred injectable tier.

Without any insurance coverage, the wholesale acquisition cost (WAC) for Mounjaro is approximately $1,023 per month for all dose strengths. Retail pharmacy pricing in Michigan ranges from roughly $1,050 to $1,200 per month depending on the pharmacy.

Lilly offers a Mounjaro Savings Card for commercially insured patients that can reduce the out-of-pocket cost to as low as $25 per fill. This card does not apply to government-insured patients (Medicare, Medicaid, Tricare). Eligible patients can check the Lilly website for current terms, which have changed several times since the program launched [6].

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Cost should not be the barrier that prevents people with type 2 diabetes from accessing medications that have demonstrated cardiovascular and glycemic benefits in rigorous clinical trials" [7].

How to Appeal a BCBSM Denial for Tirzepatide

A denial is not the final answer. Michigan law and BCBSM's own policies provide a multi-step appeal process that patients and prescribers should use aggressively when clinical evidence supports tirzepatide use.

The first step is an internal appeal filed within 60 days of the denial. The prescriber should submit a letter of medical necessity citing the patient's HbA1c trajectory, prior medication failures, and relevant trial data. The SURPASS-4 trial (N=2,002) demonstrated cardiovascular safety and sustained HbA1c reductions of 2.58% with tirzepatide 15 mg over 52 weeks versus 1.44% with insulin glargine, data that directly addresses the clinical necessity argument [8].

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "Payers need to move beyond step therapy algorithms that were designed for a different era of diabetes pharmacotherapy. The evidence base for GIP/GLP-1 receptor agonists now supports earlier use in the treatment pathway" [9].

If the internal appeal fails, patients can request an external review through an independent review organization (IRO). Michigan's DIFS oversees this process. The IRO must render a decision within 45 days for standard reviews or 72 hours for expedited reviews involving urgent clinical situations.

A peer-to-peer review is another option. The prescribing physician can request a direct conversation with BCBSM's medical director or pharmacy director to discuss the clinical rationale. These conversations often succeed when the physician can cite specific trial data and explain why alternatives are insufficient for the individual patient.

BCBSM Medicare Advantage and Medicaid Considerations

Michigan residents enrolled in BCBSM Medicare Advantage plans face different coverage rules than commercial members. Medicare Advantage plans must cover all Part D-eligible drugs, and Mounjaro is on the Part D formulary for type 2 diabetes. The prior authorization requirements still apply, and the tier placement may differ from commercial plans.

The Medicare Part D coverage gap (formerly known as the "donut hole") affects out-of-pocket costs for Mounjaro. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare Part D out-of-pocket costs are capped at $2,000 annually, which significantly reduces the financial burden for Medicare beneficiaries taking high-cost specialty medications like tirzepatide [10].

Michigan Medicaid (managed by the Michigan Department of Health and Human Services) covers Mounjaro for type 2 diabetes through its preferred drug list, though prior authorization is required. Medicaid coverage for anti-obesity medications remains limited. Patients enrolled in Healthy Michigan Plan, the state's Medicaid expansion program, follow the same formulary restrictions.

Blue Care Network, the HMO subsidiary of BCBSM, manages several Medicaid managed care contracts in Michigan. Coverage under these contracts follows state Medicaid formulary rules rather than commercial formulary rules, which can result in different tier placements and PA criteria [11].

Strategies to Maximize Your Chance of Approval

Getting tirzepatide covered requires preparation. Start with the diagnosis code. For the diabetes indication, the prescriber should use ICD-10 code E11 (type 2 diabetes mellitus) with appropriate subcodes reflecting complications. For weight management, E66.01 (morbid obesity due to excess calories) paired with relevant comorbidity codes strengthens the PA request.

Document everything before submitting the PA. A complete submission includes: current HbA1c or fasting glucose values, a list of all prior diabetes medications with start dates, stop dates, and reasons for discontinuation, body weight and BMI, relevant comorbidities (hypertension, dyslipidemia, ASCVD, CKD), and a brief statement of medical necessity from the prescriber.

Consider the timing of your PA submission. BCBSM updates its formulary annually, typically effective January 1. Mid-year formulary changes are less common but do occur, particularly when new clinical evidence or FDA label changes warrant reassessment. If a PA is denied late in the plan year, resubmitting in January under the new formulary may yield a different result.

Specialty pharmacies affiliated with BCBSM, such as AllianceRx Walgreens Pharmacy, may offer lower copays than retail pharmacies for specialty-tier medications. Ask BCBSM member services whether a preferred specialty pharmacy network applies to your plan [12].

Comparing Tirzepatide Coverage Across Michigan Insurers

BCBSM is Michigan's largest insurer, covering approximately 4.4 million members, but coverage policies vary across the state's other major carriers. Priority Health, HAP (Health Alliance Plan), Physicians Health Plan, and United Healthcare all maintain separate formularies and PA criteria for tirzepatide.

Among Michigan's major insurers, the general pattern holds: Mounjaro for type 2 diabetes is covered with prior authorization across nearly all commercial plans. Zepbound for weight loss remains excluded from most plans. The differentiators are step therapy stringency, tier placement, and preferred pharmacy requirements.

The Endocrine Society's 2024 Clinical Practice Guideline on Pharmacological Management of Obesity recommends GLP-1 and dual GIP/GLP-1 receptor agonists as first-line pharmacotherapy for adults with BMI ≥30, directly challenging the insurance industry's widespread exclusion of these medications for the obesity indication. This guideline may eventually push Michigan insurers, including BCBSM, toward broader weight management coverage [13].

Patients comparing plans during Michigan's open enrollment period (typically November through mid-January for ACA marketplace plans) should request a formulary exception estimate for tirzepatide before selecting a plan. The Summary of Benefits and Coverage (SBC) document lists whether anti-obesity medications are a covered benefit category.